Drug Approval | March 01, 2024
Biocon Biologics secures US market entry date for Bmab 1200
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
The objective of GCMC is well aligned to WHO’s call to action and India’s National Biotechnology Development Strategy
The contract awarded to Kilitch Estro Biotech PLC entails the supply of pharmaceuticals with an order size amounting to US$ 9.13 million
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
Sustainability is integral to Biocon's business purpose
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
The Board has elected Dr. Ajit Shetty, who had served as the Company's Interim Chairperson of the Board since December 9, 2023, as Chairperson of the Board, effective February 13, 2024
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
1,000 Ph.D. students will be enrolled in the next five years to drive innovation in the critical healthcare sector
Subscribe To Our Newsletter & Stay Updated
